Allurion Technologies Holdings Inc. (NYSE: ALUR) has announced preliminary, unaudited results for the second quarter of 2025, reporting approximately $3 million in revenue. The company also reported an operating loss of approximately $7 million, showing an improvement from the $9.3 million operating loss recorded in the second quarter of 2024. This improvement was partly attributed to a 50% reduction in operating expenses year-over-year. In the second quarter of 2025, the company launched several R&D, clinical, and commercial initiatives as part of its new strategic direction, which includes an increasing focus on low-dose GLP-1 combination therapy and muscle mass maintenance. The company signed a term sheet with a strategic partner to expand ex-US distribution and enhance its R&D pipeline, including the potential development of a novel GLP-1 drug-eluting intragastric balloon. Allurion also submitted a protocol for a multi-center study on combining the Allurion Program with low-dose GLP-1 for weight loss to European Institutional Review Boards for approval. The company anticipates enrollment for the study to begin within the year. Additionally, the company's PMA application for the Allurion Balloon has been successfully accepted by the FDA for evaluation. Clinics piloting the combination approach as part of a comprehensive obesity management program reported a 20% growth in the second quarter of 2025 compared to the first quarter of 2025. Allurion continues to position itself for long-term success in the obesity market, with potential US market entry on the horizon.